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In silico ADMETPentavalent antimonials have saved the lives of thousands of Leishmania-infected patients more than sev-
enty years but, unfortunately, they are highly toxic and require parenteral delivery. Therefore, the search
for safer and orally delivered alternative is a need. This paper describes the antileishmanial properties of
PMIC4, a novel hydroxyethylpiperazine analogue. PMIC4 showed potent activity against intracellular
amastigotes of Leishmania amazonensis, with IC50 of 1.8 lM and selectivity index higher than 100-fold,
calculated in relation to the toxicity on the host cell. Following laboratory animal welfare policies, we
analyzed the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties and calcu-
lated the Lipinski’s rule of ﬁve of PMIC4 before proceeding to in vivo tests. PMIC4 satisﬁed Lipinski’s rule
of ﬁve and presented high probability of human intestinal absorption, suggesting a good chance of drug-
likeness and oral bioavailability. For in vivo studies, PMIC4 was administered via intralesional injection
(3.4 mg/kg/day, three times a week) or orally (34.0 mg/kg/day, ﬁve times a week) to L. amazonensis-
infected BALB/c mice throughout the 98 day experiments. At the end of the treatment period, serum
markers of toxicity were measured. When administered orally, PMIC4 controlled the lesions in L. amazon-
ensis-infected BALB/c mice without altering serological markers of toxicity. These results demonstrate
that PMIC4 is a promising molecular scaffold, orally effective against experimental leishmaniasis.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction anti-HIV (Bhattacharya et al., 2012). In recent years, several reportsLeishmaniasis affects 2 million people each year in 98 countries
or territories (Alvar et al., 2012). Although pentavalent antimonials
have saved the lives of thousands of Leishmania-infected patients,
they are expensive, require long-term parenteral administration
and have serious side effects (Amato et al., 2008). Miltefosine, a
new orally active compound, appears to be less active against
New World leishmaniasis than it is in India (Dorlo et al., 2012).
Therefore, the search for new treatment alternatives is a priority.
Hydroxyethylamines are pharmacophore moieties present in a
variety of biological active compounds, such as b-secretase inhibi-
tors (Mondal et al., 2013), antimalarials (Jaudzems et al., 2014) andhave described the antileishmanial activity of the hydroxyethyl-
amines used in the highly active antiretroviral therapy (HAART)
(Savoia et al., 2005; Santos et al., 2009, 2013b; Griensven et al.,
2013). In a previous study, we described the synthesis and demon-
strated the antimalarial activity of a new series of hydroxyethyl-
piperazines, analogues to HIV protease inhibitors (Cunico et al.,
2009). Here, we show our results regarding the antileishmanial
activity of PMIC4, the most promising hit from this series.2. Materials and methods
2.1. Chemicals
The hydroxyethylpiperazine was synthesised in the Laboratory
of Chemical Synthesis, FIOCRUZ. Meglumine antimoniate (Glucan-
time, Sanoﬁ-Aventis) was a gift from the Instituto de Pesquisas
Evandro Chagas, FIOCRUZ.
Table 1
In silico analysis of druglikeness of PMIC4.
Lipinski molecular descriptors
NHBA (610) 7
NHBD (65) 2
clogP (65) 4.01 ± 0.69
MW (6500) 469.6
Result Probability (%)
Absorption
Blood–brain barrier  94.08
Human intestinal absorption + 62.35
Caco-2  70.92
Metabolism
CYP450 2C9 substrate NS 81.15
CYP450 2D6 substrate NS 72.71
CYP450 3A4 substrate S 72.37
CYP450 1A2 inhibitor NI 92.16
CYP450 2C9 inhibitor NI 84.45
CYP450 2D6 inhibitor NI 77.12
CYP450 2C19 inhibitor NI 81.25
CYP450 3A4 inhibitor NI 90.15
Toxicity
AMES toxicity  85.18
Carcinogens  92.12
Acute oral toxicity III 62.31
I, inhibitor; NI, noninhibitor; NS, nonsubstrate; NHBA, number of hydrogen bond
acceptors; NHBD, number of hydrogen bond donors; clogP, logarithm of compound
partition coefﬁcient between n-octanol and water; MW, molecular weight.
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Promastigotes of Leishmania amazonensis (MHOM/BR/77/
LTB0016) were maintained at 26 C in Schneider’s insect medium
(Sigma–Aldrich, St Louis, MO, USA) with 10% serum, 100 lg/mL
streptomycin and 100 U/mL penicillin until the 10th passage.
2.3. Antipromastigote activity
L. amazonensis promastigotes (1  106/mL) were incubated with
PMIC4 (up to 200 lM) for 72 h at 26 C in Schneider’s medium plus
10% serum in 96-well plates. Parasite viability was evaluated by
adding 22 lL of MTT (5 mg/mL). After 2 h, 80 lL of DMSO was
added to each well, and the optical density was measured at
570 nm.
2.4. Anti-amastigote activity
The infection of macrophages was performed as previously
described (da Cunha-Júnior et al., 2011). Brieﬂy, 2  106/mL
BALB/c peritoneal macrophages were infected with L. amazonensis
promastigotes at a 3:1 parasite/macrophage ratio in Lab-Tek cham-
bers (Nunc, Rochester, NY, USA). After 3 h of infection, PMIC4 in
RPMI medium (Sigma–Aldrich) was added for further 72 h. The
anti-amastigote activity was evaluated by counting at least 200
macrophages per sample under a microscope. The 50% inhibitory
concentration (IC50) was determined by logarithmic regression in
GraphPad Prism.
2.5. In vivo assays
BALB/c mice (5/group) were infected in the footpad with
2  106 L. amazonensis promastigotas and the treatment began
72 h after the infection. The animals were treated subcutaneously
with 3.4 mg/kg PMIC4 diluted in PBS three days a week, orally
through an orogastric tube with a suspension of 34.0 mg/kg PMIC4
diluted in PBS and 2% DMSO ﬁve days a week, or intraperitoneally
with 17 mg Sb5+/kg/day of meglumine antimoniate ﬁve days a
week; control mice remained untreated. The lesions were mea-
sured using a dial calliper every 3–4 days. At the end of the exper-
iment (day 98), the animals were euthanised, and serum was
collected for biochemical analysis. The data were analysed by
two-way ANOVA with the Bonferroni post-test.
2.6. Ethics statement
Studies in L. amazonensis-infected BALB/c mice were performed
in accordance with protocols approved by the Ethics Committee for
Animal Use of the FIOCRUZ (LW07/2010).
3. Results and discussion
3.1. Selective antileishmanial activity of PMIC4
From a series of eight hydroxyethylpiperazines evaluated for
antipromastigote activity, PMIC4 was the most potent, with IC50
of 23.2 lM. We determined that PMIC4 has activity against intra-
cellular amastigotes without affecting the host cells, with an IC50
of 1.8 lM. Although comparisons are complicated by different
methodologies, these results suggested that PMIC4 is more potent
than the HIV protease inhibitors that have already been tested
against Leishmania, as reviewed by Santos (Santos et al., 2013a).
Uninfected macrophages remained unaffected by PMIC4 up to
300 lM, indicating a selectivity greater than 100-fold higher than
the IC50 on amastigotes.3.2. In silico analysis
Before proceeding to in vivo assays, we performed some theo-
retical analysis of the druglikeness of PMIC4. The absorption, distri-
bution, metabolism, excretion and toxicity (ADMET) properties of
PMIC4 were evaluated using the admetSAR tool (Cheng et al.,
2012), and Lipinski’s rule of ﬁve was calculated using Advanced
Chemistry Development (ACD/Labs) Software V 11.02 (copyright
19942012 ACD/Labs). PMIC4 has seven hydrogen bond acceptors
and two donors, molecular weight of 469.6 and logarithm of parti-
tion coefﬁcient between n-octanol and water of 4.01, fulﬁlling the
Lipinski rule of ﬁve (Table 1). The calculated ADMET properties
indicated a good probability of PMIC4 be safe and orally absorbed
(Table 1). We found that PMIC4 is predicted as a class III risk for
acute toxicity, i.e., compounds with LD50 greater than 500 mg/kg.
The simulation also indicated that PMIC4 is not likely to act as
inhibitor of CYP3A4, unlike most HIV protease inhibitors.3.3. In vivo activity
Considering the in vitro and in silico results, we evaluated the
activity of PMIC4 in a murine model of cutaneous leishmaniasis.
Indeed, PMIC4 delivered orally was as effective as subcutaneously,
and was more effective than pentavalent antimonial in controlling
lesion development in mice (Fig. 1a). The observed therapeutic
effect was similar to that previously reported with indinavir and
ritonavir in L. amazonensis-infected BALB/c mice (Demarchi et al.,
2012). No apparent signs of toxicity were observed, and there were
no signiﬁcant differences in serological markers of toxicity
between experimental and control animals (Fig. 1b).3.4. Conclusion
The selective activity in vitro, the theoretical predictions of
druglikeness and the in vivo activity by oral administration sug-
gested PMIC4 as a good scaffold for further studies aimed at devel-
oping a drug candidate for treating leishmaniasis.
Fig. 1. PMIC4 was effective in vivo, delivered either locally or orally, without altering serological markers of toxicity. (a – insert) Schematic of the PMIC4 structure. (a) BALB/c
mice were infected in the footpad with L. amazonensis. The animals were treated subcutaneously in the infected footpad with 3.4 mg/kg PMIC4 three days a week. The oral
treatment consisted of 34.0 mg/kg PMIC4 ﬁve days a week. Control animals received either intraperitoneal injections of meglumine antimoniate (17 mg/kg Sb5+) ﬁve days a
week or were untreated. The data are presented as the mean ± standard error of 5 animals per group. ⁄p<0.05, ⁄⁄p<0.01 and ⁄⁄⁄p<0.001. Control versus Glucantime, day 91,
⁄⁄p<0.01. Control versus PMIC4 oral and intralesional PMIC4, day 63, ⁄⁄⁄p<0.001. Two-way ANOVA with the Bonferroni post-test. (b) At the end of the treatment period, serum
samples were collected, and serum toxicological markers were analysed. ns, not statistically signiﬁcant; ⁄p<0.05.
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